Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 22, 2026, Aptevo Therapeutics Inc. (the "Company") held its Special Meeting of Stockholders (the "Special Meeting"), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on August 31, 2026 (the "Proxy Statement"). The final voting results with respect to each of the proposals acted upon at the 2026 Special Meeting are set forth below.

Proposal 1: Approval of the Company's Amended and Restated Certificate of Incorporation

An amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to make certain technical and administrative changes was not approved based on the following:

Proposal 2: Approval of the issuance of common stock

The issuance of more than 20% of the Company's issued and outstanding common stock as of August 12, 2026 pursuant to the warrant reload and private placement transactions with certain holders, pursuant to Nasdaq Listing Rules 5635(d) was approved based on the following:

Proposal 3: Approval of the Company's Fifth Amended and Restated 2018 Stock Incentive Plan

The Aptevo Therapeutics Inc. Fifth Amended and Restated 2018 Stock Incentive Plan was approved based on the following votes:

Proposal 4: Authorization to adjourn the Special Meeting

The authorization to adjourn the Special Meeting to a later date, if necessary or appropriate, was approved based on the following votes: